In Vivo CAR-T Therapy

BIOLOGICAL2 trials

Sponsors

Shanghai Zhongshan Hospital, Tcelltech Inc.

Conditions

Graves' DiseaseRelapsed or Refractory Hematologic Malignancies

Early Phase 1

In Vivo CAR-T for Refractory Graves' Disease

RecruitingNCT07333677

Shanghai Zhongshan HospitalGraves' Disease

Start: 2026-01-29End: 2027-12-01Target: 5Updated: 2026-03-19

Phase 1

Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies

Not yet recruitingNCT07485504

Tcelltech Inc.Relapsed or Refractory Hematologic Malignancies

Start: 2026-04-15End: 2028-10-15Target: 15Updated: 2026-03-20